Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NUVL
NUVL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NUVL News
Nuvalent Submits NDA for Lung Cancer Drug, Advancing Treatment Options
4d ago
PRnewswire
Guardant Health and Nuvalent Forge Long-Term Partnership to Create Companion Diagnostics and Aid in the Commercialization of Targeted Cancer Treatments via the Guardant Infinity™ Platform
Apr 30 2026
moomoo
Nuvalent Announces Clinical Trial Data Presentation
Apr 21 2026
PRnewswire
Nuvalent Presents Clinical Trial Data for Cancer Treatments
Apr 21 2026
Newsfilter
Zidesamtinib Shows Promising Activity in ROS1-Positive NSCLC Patients
Apr 17 2026
PRnewswire
Nuvalent Submits NDA for Neladalkib in Advanced NSCLC
Apr 07 2026
NASDAQ.COM
Nuvalent Submits NDA for ALK-Selective Inhibitor in Advanced NSCLC
Apr 07 2026
PRnewswire
Nuvalent Submits NDA for ALK-Selective Inhibitor in Advanced NSCLC
Apr 07 2026
Newsfilter
Latest Wall Street Rating Updates
Mar 30 2026
CNBC
Wells Fargo Begins Coverage of Nuvalent, Inc. with Overweight Rating and $116 Target Price
Mar 30 2026
moomoo
S&P 500 Futures Decline in Pre-Market Trading; Nuvalent and Figure Tech Solutions Take the Lead
Mar 26 2026
Barron's
Nuvalent (NUVL.US) Executive Plans to Sell $5.73 Million in Common Stock via Form 144
Mar 24 2026
moomoo
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
Mar 17 2026
PRnewswire
Nuvalent Presents New Data on Zidesamtinib at AACR 2026
Mar 17 2026
Newsfilter
Vestal Point Capital Sells Nuvalent Shares Worth $103.93 Million
Mar 17 2026
Fool
Vestal Point Capital Sells Nuvalent Shares Worth $103.93 Million
Mar 17 2026
NASDAQ.COM
Show More News
